Initiates Coverage on Aptevo Therapeutics (NASDAQ:APVO) initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVOGet Free Report) in a report issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Aptevo Therapeutics Price Performance

Shares of Aptevo Therapeutics stock opened at $0.30 on Tuesday. The company has a 50-day moving average of $0.69 and a two-hundred day moving average of $3.68. Aptevo Therapeutics has a 12-month low of $0.28 and a 12-month high of $80.96.

Aptevo Therapeutics (NASDAQ:APVOGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($9.95) earnings per share for the quarter, beating the consensus estimate of ($14.10) by $4.15. As a group, equities research analysts forecast that Aptevo Therapeutics will post -8.86 earnings per share for the current year.

About Aptevo Therapeutics

(Get Free Report)

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Further Reading

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with's FREE daily email newsletter.